Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

8.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.3K
RNA Interference01:23

RNA Interference

28.6K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective silencing of placental anti-angiogenic factors in invasive trophoblasts via membrane-fusion divalent siRNA delivery for preeclampsia therapy.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Corrigendum to "Total flavonoids of Flos Chrysanthemi protect arterial endothelial cells against oxidative stress" [J. Ethnopharmacol. 139 (2012) 68-73].

Journal of ethnopharmacology·2026
Same author

Calycosin-7-O-β-D-Glucoside Facilitates Axonal Regrowth and Functional Recovery via Rho/ROCK Pathway Inhibition After Cerebral Ischemia/Reperfusion.

International journal of molecular sciences·2026
Same author

Pharmacokinetics and qualitative metabolite profiling of major alkaloids in rats after acupoint administration of Xiatianwu Injection.

Journal of pharmaceutical and biomedical analysis·2026
Same author

Placenta-oriented self-assembled Aspirin-RGDV nanoconjugates attenuate preeclampsia through restoration of angiogenic balance.

International journal of pharmaceutics: X·2026
Same author

Pollen of Brassica campestris L. ameliorates hyperuricemic and obstructive nephropathy by targeting the β-catenin/TCF4-ferroptosis pathway.

Journal of ethnopharmacology·2026

Related Experiment Video

Updated: Mar 30, 2026

DNA Vector-based RNA Interference to Study Gene Function in Cancer
13:10

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

21.1K

Three new shRNA expression vectors targeting the CYP3A4 coding sequence to inhibit its expression.

Siyun Xu1, Yongsheng Xiao1, Li Li1

  • 1Department of Pharmaceutical Analysis and Drug Metabolism, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

Acta Pharmaceutica Sinica. B
|November 19, 2015
PubMed
Summary

Short hairpin RNA (shRNA) effectively silences the Cytochrome P450 3A4 (CYP3A4) gene, crucial for drug metabolism. This targeted gene silencing reduces CYP3A4 expression, impacting drug metabolism and toxicity studies.

Keywords:
CYP3A4ChemosensitivityCytochrome P450RNAishRNA

More Related Videos

Stable Knockdown of Genes Encoding Extracellular Matrix Proteins in the C2C12 Myoblast Cell Line Using Small-Hairpin shRNA
12:19

Stable Knockdown of Genes Encoding Extracellular Matrix Proteins in the C2C12 Myoblast Cell Line Using Small-Hairpin shRNA

Published on: February 12, 2020

8.6K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K

Related Experiment Videos

Last Updated: Mar 30, 2026

DNA Vector-based RNA Interference to Study Gene Function in Cancer
13:10

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

21.1K
Stable Knockdown of Genes Encoding Extracellular Matrix Proteins in the C2C12 Myoblast Cell Line Using Small-Hairpin shRNA
12:19

Stable Knockdown of Genes Encoding Extracellular Matrix Proteins in the C2C12 Myoblast Cell Line Using Small-Hairpin shRNA

Published on: February 12, 2020

8.6K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K

Area of Science:

  • Pharmacogenomics
  • Molecular Biology
  • Drug Metabolism Research

Background:

  • Cytochrome P450 3A4 (CYP3A4) is a key enzyme metabolizing approximately 50% of clinical drugs.
  • Modulating CYP3A4 expression is critical for understanding drug metabolism and toxicity.
  • RNA interference (RNAi) offers a method for selective gene silencing.

Purpose of the Study:

  • To develop short hairpin RNA (shRNA) constructs targeting Cytochrome P450 3A4 (CYP3A4) for gene silencing.
  • To evaluate the efficacy of designed shRNAs in reducing CYP3A4 expression in cellular models.
  • To assess the impact of CYP3A4 modulation on cellular sensitivity to specific toxins.

Main Methods:

  • Design and cloning of three novel shRNAs (S1, S2, S3) targeting the CYP3A4 coding sequence (CDS).
  • Transfection of shRNA expression vectors into CHL, HEK293, and HepG2 cells.
  • Quantification of CYP3A4 activity using CDS-luciferase assays and measurement of endogenous CYP3A4 mRNA and protein levels.
  • Assessment of gene expression selectivity by evaluating CYP3A5 levels.
  • Testing cellular sensitivity to Ginkgolic acids post-transfection.

Main Results:

  • A mixture of three shRNAs achieved optimal reduction (55%) in CYP3A4 CDS-luciferase activity in CHL and HEK293 cells.
  • Transfection of the shRNA mixture decreased endogenous CYP3A4 expression by approximately 50% at both mRNA and protein levels in HepG2 cells.
  • CYP3A5 gene expression remained unaltered, confirming the selectivity of the developed CYP3A4 shRNAs.
  • HepG2 cells transfected with CYP3A4 shRNAs exhibited reduced sensitivity to Ginkgolic acids.

Conclusions:

  • Vector-based shRNAs effectively modulate CYP3A4 expression by targeting its coding sequence.
  • The developed CYP3A4-specific shRNAs demonstrate potential for investigating CYP3A4's role in drug metabolism and toxicity.
  • This approach provides a tool for studying drug interactions and developing targeted therapies.